Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience.
Tropé C, Hogberg T, Kaern J, Bertelsen K, Bjorkholm E, Boman K, Himmelmann A, Horvath G, Jacobsen A, Kuoppola T, Vartianen J, Lund B, Onsrud M, Puistola U, Salmi T, Scheistroen M, Sandvei R, Simonsen E, Sorbe B, Tholander B, Westberg R. Tropé C, et al. Among authors: bertelsen k. Ann Oncol. 1998 Dec;9(12):1301-7. doi: 10.1023/a:1008400324892. Ann Oncol. 1998. PMID: 9932160 Free article. Clinical Trial.
Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A.
Sundfør K, Tropé CG, Högberg T, Onsrud M, Koern J, Simonsen E, Bertelsen K, Westberg R. Sundfør K, et al. Among authors: bertelsen k. Cancer. 1996 Jun 1;77(11):2371-8. doi: 10.1002/(SICI)1097-0142(19960601)77:11<2371::AID-CNCR28>3.0.CO;2-T. Cancer. 1996. PMID: 8635109 Clinical Trial.
Advanced ovarian cancer. Dose intensity.
Ozols RF, Thigpen JT, Dauplat J, Colombo N, Piccart MJ, Bertelsen K, Levin L, Lund B. Ozols RF, et al. Among authors: bertelsen k. Ann Oncol. 1993;4 Suppl 4:49-56. Ann Oncol. 1993. PMID: 8312201 Review.
Advanced epithelial ovarian cancer: 1998 consensus statements.
Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Lück HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al. Berek JS, et al. Among authors: bertelsen k. Ann Oncol. 1999;10 Suppl 1:87-92. doi: 10.1023/a:1008323922057. Ann Oncol. 1999. PMID: 10219460
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Mangioni C, Simonsen E, James K, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lidvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Pecorelli S, Baron B, McGuire W. Piccart MJ, et al. Among authors: bertelsen k. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:144-8. doi: 10.1111/j.1525-1438.2003.13357.x. Int J Gynecol Cancer. 2003. PMID: 14656271 Clinical Trial.
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results.
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S. Piccart MJ, et al. Among authors: bertelsen k. J Natl Cancer Inst. 2000 May 3;92(9):699-708. doi: 10.1093/jnci/92.9.699. J Natl Cancer Inst. 2000. PMID: 10793106 Clinical Trial.
106 results